Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

Tue, 06/25/2019 - 3:50pm

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but...

      Related Stories 

Conatus Accepts Defeat For Emricasan In NASH

Tue, 06/25/2019 - 1:32pm

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was...

      Related Stories 

Glenmark Boosts Respiratory Thrust In Brazil With Novartis Deal

Tue, 06/25/2019 - 9:02am

Glenmark will market three COPD therapies from Novartis in Brazil and expects a significant uptick in its Latin America business...

      Related Stories 

Cautious Restart To Venetoclax’s CANOVA Trial In Multiple Myeloma

Tue, 06/25/2019 - 7:05am

The US FDA has lifted a partial clinical hold on one study of venetoclax in multiple myeloma, but other trials...

      Related Stories 

BMS' Bid For Opdivo In First-Line HCC Stymied

Mon, 06/24/2019 - 1:51pm

Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target...

      Related Stories 

Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity

Mon, 06/24/2019 - 12:30pm

As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if...

      Related Stories 

Bring Them On: China Releases Generics List To Encourage Competition

Mon, 06/24/2019 - 2:10am

China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.

      Related Stories 

CHART/TABLE: Pipeline Watch: Phase III Read-Outs For Zanubrutinib, Surufatinib

Mon, 06/24/2019 - 1:49am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Chugai Expects Limited Impact From First Biosimilar To Top Seller

Sun, 06/23/2019 - 11:55pm

First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and...

      Related Stories 

Chugai Expects Limited Impact From First Biosimilar To Its Top Seller

Sun, 06/23/2019 - 11:55pm

First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and...

      Related Stories 

Product Licensing Deals In India Paying Off?

Sun, 06/23/2019 - 6:57pm

India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements...

      Related Stories 

Sanofi Plans More Job Cuts, This Time In R&D

Sun, 06/23/2019 - 3:56pm

The French pharma giant will cut 466 posts in France and Germany. Cardiovascular and diabetes research will be scaled back.

      Related Stories 

Novumcella Building Exosome Expertise In Inflammatory Disorders

Fri, 06/21/2019 - 12:17pm

Tokyo-based Novumcella Inc. is progressing several still preclinical stage assets derived from academic research, with a focus on the intractable...

      Related Stories 

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Fri, 06/21/2019 - 12:12pm

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the...

      Related Stories 

Doubts Raised Over Regeneron’s Anti-IL 33 REGN3500 At Phase II In Asthma

Fri, 06/21/2019 - 8:13am

Topline data from a Phase II proof-of-concept study evaluating anti-IL-33 monotherapy REGN3500 (SAR440340) in asthma suggest it is not as...

      Related Stories 

Pages